Oman Journal of Ophthalmology

REVIEW ARTICLE
Year
: 2018  |  Volume : 11  |  Issue : 3  |  Page : 195--199

Glaucoma medications in pregnancy


M Reza Razeghinejad 
 Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA

Correspondence Address:
Dr. M Reza Razeghinejad
840 Walnut Street, Suite 1140, Philadelphia, PA 19107
USA

Glaucoma is a chronic, progressive disease of the optic nerve which is relatively uncommon in childbearing age; however, its management is a real challenge. Although the intraocular pressure decreases in pregnancy, many glaucoma patients continue to require treatment. In addition to the side effects, antiglaucoma medications on the mother, the possible side effects of drugs on the fetus must be taken into account. The only antiglaucoma medication categorized in Category B is brimonidine, and all others are in Category C. Most evidence on glaucoma medications in pregnancy comes from single case reports or animal studies with the limitations that these impose. Theoretically, glaucoma medications may damage the fetus; however, they may not have substantial clinical significance with routine dosages and no topical antiglaucoma agents have strong evidence of safety to the fetus based on the human studies. When discussing possible options for glaucoma management with the pregnant patient, it is important to emphasize the lack of definitive studies and the patient may be involved in the therapeutic decision-making process.


How to cite this article:
Razeghinejad M R. Glaucoma medications in pregnancy.Oman J Ophthalmol 2018;11:195-199


How to cite this URL:
Razeghinejad M R. Glaucoma medications in pregnancy. Oman J Ophthalmol [serial online] 2018 [cited 2018 Dec 11 ];11:195-199
Available from: http://www.ojoonline.org/article.asp?issn=0974-620X;year=2018;volume=11;issue=3;spage=195;epage=199;aulast=Razeghinejad;type=0